Dr. Langer Adds Transdermal Drug Delivery Expertise to a Team of Scientific Advisors Led by Dr. Raphael Mechoulam and Other Pioneers in the Field of Cannabis Research
Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, today announced the appointment of Dr. Robert S. Langer to Kalytera’s Scientific Advisory Board.
Dr. Langer is a David H. Koch Institute Professor at the Massachusetts Institute of Technology (“MIT”). He is a prolific biotechnologist, engineer, and inventor who is widely recognized for his contributions to the drug delivery and tissue engineering fields. His research laboratory at MIT is the largest biomedical engineering lab in the world, employing over 100 persons.
Dr. Langer has received over 220 major awards. He is one of four living individuals to have received both the U.S. National Medal of Science and the U.S. National Medal of Technology and Innovation. He also received the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, the Millennium Prize, the world’s largest technology prize, and the Priestley Medal, the highest award of the American Chemical Society.
Dr. Robert S. Langer
“We are honored to have Dr. Langer as a member of our team,” said Dr. Raphael Mechoulam, Ph.D., Co-Chair of Kalytera’s Scientific Advisory Board. “He is a pioneer of many new technologies, including controlled release systems and transdermal delivery systems, which allow for the administration of drugs through the skin. His extensive experience and advice will help inform our technical development and commercialization efforts.”
“Transdermal delivery of cannabidiol, and other proprietary cannabinoids, may confer a variety of benefits to patients,” said Dr. Langer. “I look forward to working with Kalytera’s leadership to evaluate and optimally advance the company’s portfolio of drug candidates for bone health.”
About Robert S. Langer
Robert S. Langer is the David H. Koch Institute Professor at the Massachusetts Institute of Technology (“MIT”). He is a prolific biotechnologist, engineer, entrepreneur, and inventor who is widely recognized in biotechnology, especially in the fields of drug delivery systems. Dr. Langer has over 1,100 issued and pending patents worldwide; his patents have been licensed or sublicensed to over 300 pharmaceutical, chemical, biotechnology, and medical device companies.
Dr. Langer has received over 220 major awards. He is one of four living individuals to have received both the U.S. National Medal of Science and the U.S. National Medal of Technology and Innovation. He also received the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, the Millennium Prize, the world’s largest technology prize, the Priestley Medal, the highest award of the American Chemical Society, the Wolf Prize in Chemistry, the Breakthrough Prize in Life Sciences, and the Kyoto Prize, among many others.
Dr. Langer served as a member of the U.S. FDA’s SCIENCE Board from 1995-2002 and as its Chairman from 1999-2002. He previously served as a director of Momenta Pharmaceuticals from 2001 to 2009, Wyeth Pharmaceuticals from 2004 to 2009, and Millipore Corporation from 2009 to 2010.
Dr. Langer has received honorary doctorates from 24 universities globally, including Harvard University, the Mt. Sinai School of Medicine, Yale University, and the Hebrew University of Jerusalem (Israel). He received his Bachelor’s Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974.
Kalytera Therapeutics is developing a portfolio of non-psychoactive cannabinoid and endocannabinoid-like medicines intended to address the unmet needs of large patient populations. Kalytera seeks to commercialize its proprietary synthetic cannabinoid therapies across a range of disease states, with an initial focus on bone health.
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of Kalytera. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to Kalytera cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, Kalytera will not obtain appropriate or necessary governmental approvals to market these or other potential products, Kalytera may not be able to obtain anticipated funding for its development projects or other needed funding, and Kalytera may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and Kalytera does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.